No doubt MVH has had a lot of growing pains, and its really terrible to see the shareprice fall back to this level, but its hard to see it staying at this level for too much longer. The dump we had to have i suppose and i think some lessons learned on all sides ... ive certainly taken a few licks over this one
But, the drivers for growth are there and this speil off the RCS eagle project website in UK pretty much sums up what MVH has going for it. And this is just the situation in the UK ... Medicvision will be taking a training centre model into China and India to operate training courses for the growing surgical markets in those huge markets.
** drivers for the eagle project
Less time to train. Today’s surgical trainee spends 15,000 hours in training compared with 35,000 hours 10 years ago; a 40% reduction in training time. This is because the mandated shorter working week as a result of the EWTD and a shorter career path due to MMC.
Changing boundaries. Increasingly specialised knowledge combined with advancing technologies and drug therapies is removing traditional professional boundaries so that a broader based medical team is needed at the bedside.
Shortfall in anatomy training. There is also overwhelming evidence of a severe shortage of postgraduate surgical anatomy training.
Technological advances. In the last 10 years, over 150 new surgical procedures have been developed this requires specialised teaching facilities and an expert teaching faculty.
More need than ever for courses. The surgical workforce is expanding and, as a result, demand for surgical training is rising. Provision of courses at basic level is predicted to increase by 80-90% for the London deaneries alone, whilst new specialty courses are set to increase by 25% to serve approximately 3,000 trainees. In addition, the implementation of the surgical curriculum heralds a new requirement for a nationally run multiprofessional development programme and CPD.
****
So now let's consider where medicvision is at ...
Has cash in the bank .. let's say $2.2million ... another 13million KSX worth $3million, with the possibility for another 25million shares ($6m) should pulmosonix meet the milestones. So dilution should not be a problem ...
The India and China MOU's point to a joint roll out of MTC's in those nations ... question becomes how quickly can they roll them out and how quickly can they start getting recurring revenue on these centres ???
They will still be selling sims out of the box on licence, but hopefully they will start to sell more high margin mediseus products into US .... Cochlear sim ... any chance we will see bulk orders for this product? if so that's almost a company maker right there.
interesting times. Im thinking it should recover in the lead up to Christmas, with 2008 perhaps finally offering vindication for those who have stuck. I won't be selling too early in the next run ... i think (provided they meet their revenue targets and can roll out the MTC business plan) this one will go from strength to strength once it gets the markets attention.
No doubt MVH has had a lot of growing pains, and its really...
Add to My Watchlist
What is My Watchlist?